Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,520 GBX | +6.67% | +8.19% | +123.53% |
Jun. 05 | 4basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Business Summary
Number of employees: 78
Sales per Business
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Synthetic DNA and RNA Products
92.5
%
| 0 | 95.0 % | 0 | 92.5 % | -22.74% |
Licences and Royalties
7.5
%
| 0 | 5.0 % | 0 | 7.5 % | +17.65% |
Sales per region
GBP in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
60.4
%
| 0 | 69.5 % | 0 | 60.4 % | -31.06% |
Europe
31.7
%
| 0 | 24.3 % | 0 | 31.7 % | +3.66% |
Rest of World
7.8
%
| 0 | 6.2 % | 0 | 7.8 % | 0.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - | |
Chairman | 68 | 20-12-21 | |
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
Director/Board Member | 55 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,805,208 | 3,889,907 ( 30.38 %) | 0 | 30.38 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+123.53% | 233M | |
+55.55% | 59.34B | |
+43.17% | 40.24B | |
-4.71% | 39.88B | |
-5.56% | 28.55B | |
+13.76% | 27.26B | |
-22.00% | 19.23B | |
+31.50% | 12.61B | |
+2.16% | 12.49B | |
+25.70% | 12.28B |
- Stock Market
- Equities
- 4BB Stock
- Company 4basebio PLC